Welcome to our dedicated page for Genmab news (Ticker: GMAB), a resource for investors and traders seeking the latest updates and insights on Genmab stock.
Genmab A/S (GMAB) is a global biotechnology leader focused on creating differentiated antibody therapies for cancer and autoimmune diseases. This page serves as the definitive source for Genmab news, providing investors and industry professionals with timely updates on clinical developments, regulatory milestones, and strategic partnerships.
Access consolidated information on FDA approvals, collaboration announcements, and clinical trial results across Genmab's pipeline. The company's proprietary platforms like DuoBody and HexaBody underpin its innovative treatments, with key alliances including Johnson & Johnson and AbbVie driving therapeutic advancements.
Bookmark this page for real-time updates on Genmab's progress in antibody engineering and commercialization efforts. Monitor critical updates through verified press releases while gaining insights into how the company addresses complex medical challenges through targeted biologics.
Genmab A/S (Nasdaq: GMAB) announced the submission of a Japan New Drug Application (JNDA) for epcoritamab, an investigational bispecific antibody targeting relapsed/refractory large B-cell lymphoma (LBCL). This submission is backed by results from Japanese and global phase 2 clinical trials. Epcoritamab's ongoing development involves collaboration with AbbVie, with shared responsibilities for commercialization in the U.S. and Japan. The treatment shows promise as a therapeutic option for patients requiring alternative therapies.
Genmab A/S (Nasdaq: GMAB) has announced promising results from multiple clinical trials involving epcoritamab, an investigational bispecific antibody targeting B-cell malignancies. Notable findings include an 85% overall response rate in a phase 1b/2 trial for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and high response rates in follicular lymphoma. Epcoritamab is co-developed with AbbVie and is undergoing regulatory review, with an FDA action date of May 21, 2023. The breadth of data presented at the American Society of Hematology annual meeting underscores Genmab's commitment to addressing critical treatment needs.
Genmab (NASDAQ: GMAB) announced the acceptance of 19 abstracts for the 64th Annual Meeting of the American Society of Hematology (ASH) taking place December 10-13, showcasing investigational therapies including epcoritamab. The data will feature four oral presentations on epcoritamab's efficacy in treating various B-cell malignancies. The company will present early data on GEN3014 and GEN3017. A 2022 R&D Update and ASH Data Review meeting is scheduled for December 12.
Genmab has submitted a Biologics License Application (BLA) to the U.S. FDA for epcoritamab, a bispecific antibody targeting relapsed/refractory large B-cell lymphoma. AbbVie has also validated a Marketing Authorization Application (MAA) for epcoritamab with the European Medicines Agency (EMA). These submissions stem from the EPCORE NHL-1 phase 2 trial, showing the drug's safety and efficacy in treating CD20+ mature B-cell non-Hodgkin lymphoma, a significant medical need exists for these patients. The joint development with AbbVie aims to bring new therapeutic options to market.
Zai Lab has secured exclusive rights to develop and commercialize TIVDAK, an FDA-approved antibody-drug conjugate, in Mainland China, Hong Kong, Macau, and Taiwan. The collaboration with Seagen involves a $30 million upfront payment, milestone payments, and shared royalties. TIVDAK addresses a significant unmet need in treating recurrent or metastatic cervical cancer, with 110,000 new cases annually in China. Ongoing clinical trials underpin the therapeutic potential of TIVDAK in various cancer treatments.
FAQ
What is the current stock price of Genmab (GMAB)?
What is the market cap of Genmab (GMAB)?
